Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

8.6K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.6K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microfluidic Modeling of Macrophage-Induced Cardiac Inflammation Using NF-κB Reporter Cardiomyocytes.

Advanced healthcare materials·2026
Same author

NF-κB c-Rel is a critical regulator of TLR7-induced inflammation in psoriasis.

EBioMedicine·2024
Same author

Role of Sam68 as an adaptor protein in inflammatory signaling.

Cellular and molecular life sciences : CMLS·2024
Same author

Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy.

PloS one·2022
Same author

Sam68 contributes to intestinal inflammation in experimental and human colitis.

Cellular and molecular life sciences : CMLS·2021
Same author

Negative regulation of FOXP3 expression by c-Rel O-GlcNAcylation.

Glycobiology·2021

Related Experiment Video

Updated: May 5, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Targeting WNK1 Releases Differentiation Block in Acute Myeloid Leukemia.

Jordan D Cress1,2, Emily M Katoni1, Parameswaran Ramakrishnan1,3,4,5,2

  • 1Department of Pathology, Case Western Reserve University, 2103 Cornell Road, Cleveland, Ohio 44106, USA.

Biorxiv : the Preprint Server for Biology
|May 4, 2026
PubMed
Summary

With-no-Lysine(K) kinase 1 (WNK1) drives Acute Myeloid Leukemia (AML) by blocking cell maturation. Inhibiting WNK1 promotes AML cell differentiation and reduces tumor growth, offering a new therapeutic strategy.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.0K

Related Experiment Videos

Last Updated: May 5, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Impaired myeloid differentiation is a key feature of Acute Myeloid Leukemia (AML).
  • Current differentiation therapies are effective for only a limited number of AML patients, highlighting the need for new therapeutic targets.
  • Understanding the molecular mechanisms of differentiation arrest is crucial for developing broader AML treatments.

Purpose of the Study:

  • To identify novel molecular regulators of AML differentiation arrest.
  • To investigate the role of With-no-Lysine(K) kinase 1 (WNK1) in AML pathogenesis.
  • To evaluate WNK1 inhibition as a potential therapeutic strategy for AML.

Main Methods:

  • Analysis of WNK1 expression and activity in AML patient samples.
  • In vitro studies using AML cell lines and patient-derived cells to assess the effects of WNK1 inhibition on differentiation, proliferation, and self-renewal.
  • In vivo studies using mouse models to evaluate the anti-tumor activity of WNK1 inhibition.
  • Mechanistic studies to elucidate the signaling pathways affected by WNK1 inhibition.

Main Results:

  • WNK1 expression and activity are significantly elevated in AML patients.
  • Inhibition of WNK1 in AML cells induced myeloid differentiation, decreased cell growth and survival, and impaired self-renewal.
  • WNK1 inhibition demonstrated significant anti-tumor activity in preclinical mouse models of AML.
  • Mechanistically, WNK1 inhibition led to the reactivation of the MEK-ERK-C/EBPβ signaling pathway and increased myeloid differentiation gene expression.

Conclusions:

  • WNK1 plays a critical role in promoting AML by inducing differentiation arrest.
  • WNK1 inhibition represents a promising novel therapeutic approach for a broader spectrum of AML patients.
  • Targeting WNK1 could overcome differentiation blockades in AML and restore normal myeloid development.